{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:09:08Z","timestamp":1788296948131,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier","isbn-type":[{"value":"9780443344817","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.acr.2025.06.004","type":"book-chapter","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:49:22Z","timestamp":1750780162000},"page":"196-220","source":"Crossref","is-referenced-by-count":4,"title":["Michael addition drugs and cancer"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acr.2025.06.004_bib1","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1039\/D2OB02262A","article-title":"Thia-Michael addition: The route to promising opportunities for fast and cysteine-specific modification","volume":"21","author":"Ahangarpour","year":"2023","journal-title":"Organic & Biomolecular Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12903-024-04045-8","article-title":"A systematic review and meta-analysis of the impact of resveratrol on oral cancer: Potential therapeutic implications","volume":"24","author":"Alam","year":"2024","journal-title":"BMC Oral Health"},{"key":"10.1016\/bs.acr.2025.06.004_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142580","article-title":"The bright side of curcumin: A narrative review of its therapeutic potential in cancer management","volume":"16","author":"Amaroli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.acr.2025.06.004_bib4","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.2741\/begleit","article-title":"Clinical applications of quinone-containing alkylating agents","volume":"5","author":"Begleiter","year":"2000","journal-title":"Frontiers in Bioscience: a Journal and Virtual Library"},{"key":"10.1016\/bs.acr.2025.06.004_bib5","doi-asserted-by":"crossref","first-page":"14614","DOI":"10.1021\/acs.jmedchem.2c01120","article-title":"Fragment optimization of reversible binding to the switch II pocket on KRAS leads to a potent, in vivo active KRAS(G12C) inhibitor","volume":"65","author":"Broker","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30678-8","article-title":"Preliminary activity of capmatinib with gefitinib in NSCLC","volume":"19","author":"Burki","year":"2018","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.acr.2025.06.004_bib7","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286537","article-title":"Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib","author":"Carraway","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/bs.acr.2025.06.004_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0021-9258(19)84014-0","article-title":"Inhibition of electron and energy transfer in mitochondria. I. Effects of Amytal, thiopental, rotenone, progesterone, and methylene glycol","volume":"238","author":"Chance","year":"1963","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/v13091756","article-title":"Identification of potential drug targets of broad-spectrum inhibitors with a Michael acceptor moiety using shotgun proteomics","volume":"13","author":"Chu","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/bs.acr.2025.06.004_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0305-7372(76)80019-9","article-title":"Mitomycin C: A review","volume":"3","author":"Crooke","year":"1976","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/bs.acr.2025.06.004_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/00003495-200969070-00006","article-title":"Bortezomib: A review of its use in patients with multiple myeloma","volume":"69","author":"Curran","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/bs.acr.2025.06.004_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.acr.2025.06.004_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/17512433.2021.1901578","article-title":"Activation of Nrf2 signaling pathway by natural and synthetic chalcones: A therapeutic road map for oxidative stress","volume":"14","author":"Egbujor","year":"2021","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/bs.acr.2025.06.004_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1574892814666190514104035","article-title":"Repurposing Disulfiram as an Anti-Cancer Agent: Updated Review on Literature and Patents","volume":"14","author":"Ekinci","year":"2019","journal-title":"Recent Patents on Anti-Cancer Drug Discovery"},{"key":"10.1016\/bs.acr.2025.06.004_bib15","doi-asserted-by":"crossref","first-page":"10367","DOI":"10.1073\/pnas.94.19.10367","article-title":"Broccoli sprouts: An exceptionally rich source of inducers of enzymes that protect against chemical carcinogens","volume":"94","author":"Fahey","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.acr.2025.06.004_bib16","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1097\/MS9.0000000000002045","article-title":"Pirtobrutinib: A promising therapy for overcoming the resistance of ibrutinib in mantle cell lymphoma","volume":"86","author":"Fatima","year":"2024","journal-title":"Annals of Medicine and Surgery"},{"key":"10.1016\/bs.acr.2025.06.004_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/ggi.14939","article-title":"Nrf2 cell signaling pathway is responsible for the antioxidant effect of resveratrol in aging","volume":"24","author":"Franco","year":"2024","journal-title":"Geriatrics & Gerontology International"},{"key":"10.1016\/bs.acr.2025.06.004_bib18","first-page":"962","article-title":"The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models","volume":"7","author":"Friese-Hamim","year":"2017","journal-title":"American Journal of Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/mol.53.3.422","article-title":"The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II\/DNA cleavable complex","volume":"53","author":"Gantchev","year":"1998","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.acr.2025.06.004_bib20","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","article-title":"Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo","volume":"13","author":"Gills","year":"2007","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112962","article-title":"A comprehensive review on beta-lapachone: Mechanisms, structural modifications, and therapeutic potentials","volume":"210","author":"Gong","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2025.06.004_bib23","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1074\/jbc.M110.178806","article-title":"Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin","volume":"286","author":"Griesser","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1155163","article-title":"Anti-cancer activity of guggulsterone by modulating apoptotic markers: a systematic review and meta-analysis","volume":"14","author":"Gupta","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.acr.2025.06.004_bib25","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1124\/jpet.103.050070","article-title":"Kinetics of NAD(P)H: Quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo","volume":"305","author":"Gustafson","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.acr.2025.06.004_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0891-5849(00)00314-2","article-title":"The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: A review","volume":"29","author":"Gutierrez","year":"2000","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/bs.acr.2025.06.004_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/srep38973","article-title":"Antibacterial and anticancer PDMS surface for mammalian cell growth using the Chinese herb extract paeonol(4-methoxy-2-hydroxyacetophenone)","volume":"6","author":"Jiao","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.acr.2025.06.004_bib28","doi-asserted-by":"crossref","unstructured":"Kim et al., FEBS Lett 2021, vol 595 issue 5 pages 604-622Accession # 33452674. https:\/\/doi.org\/10.1002\/1873-3468.14040.","DOI":"10.1002\/1873-3468.14040"},{"key":"10.1016\/bs.acr.2025.06.004_bib29","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0022-3565(25)22526-5","article-title":"Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer","volume":"270","author":"Lacreta","year":"1994","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.acr.2025.06.004_bib30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1124\/pr.111.004846","article-title":"Synthetic oleanane triterpenoids: Multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease","volume":"64","author":"Liby","year":"2012","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/bs.acr.2025.06.004_bib31","doi-asserted-by":"crossref","first-page":"58038","DOI":"10.18632\/oncotarget.10846","article-title":"Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acr.2025.06.004_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tox.2019.02.005","article-title":"Mechanisms of soft and hard electrophile toxicities","volume":"418","author":"LoPachin","year":"2019","journal-title":"Toxicology"},{"key":"10.1016\/bs.acr.2025.06.004_bib33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","article-title":"Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C","volume":"15","author":"Maciag","year":"2025","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2025.06.004_bib34","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","article-title":"Selpercatinib: First approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/bs.acr.2025.06.004_bib35","doi-asserted-by":"crossref","first-page":"9965","DOI":"10.1021\/acs.jmedchem.0c01088","article-title":"CDDO-imidazolide targets multiple amino acid residues on the Nrf2 adaptor, Keap1","volume":"63","author":"Meng","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib36","first-page":"1","article-title":"Ueber die Addition des Enolats an die unges\u00e4ttigten Carbonylverbindungen","volume":"236","author":"Michael","year":"1887","journal-title":"Annalen der Chemie und Pharmacie"},{"key":"10.1016\/bs.acr.2025.06.004_bib37","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ejh.12749","article-title":"A practical review on carfilzomib in multiple myeloma","volume":"96","author":"Muchtar","year":"2016","journal-title":"European Journal of Haematology"},{"key":"10.1016\/bs.acr.2025.06.004_bib38","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2174\/1871520620666200918100833","article-title":"Anti-cancer effect of gingerol in cancer prevention and treatment","volume":"21","author":"Nafees","year":"2021","journal-title":"Anti-cancer Agents in Medicinal Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib39","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-3565(24)39096-2","article-title":"The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance","volume":"294","author":"O\u2019Brien","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.acr.2025.06.004_bib40","first-page":"6059","article-title":"Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid","volume":"51","author":"O\u2019Dwyer","year":"1991","journal-title":"Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib41","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.acr.2025.06.004_bib42","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm4061325","article-title":"Horizon 2020 in diabetic kidney disease: The clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade","volume":"4","author":"Perez-Gomez","year":"2015","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.acr.2025.06.004_bib43","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders","volume":"57","author":"Petrakis","year":"2005","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.acr.2025.06.004_bib44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0010-4035(70)90064-9","article-title":"The site of action of the diuretic ethacrynic acid on rat kidney and liver tissue","volume":"1","author":"Poat","year":"1970","journal-title":"Comparative and General Pharmacology"},{"key":"10.1016\/bs.acr.2025.06.004_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-4165(97)00104-9","article-title":"The mode of action of allicin: Trapping of radicals and interaction with thiol containing proteins","volume":"1379","author":"Rabinkov","year":"1998","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/bs.acr.2025.06.004_bib46","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2025.06.004_bib47","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: Preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0753-3322(01)00158-5","article-title":"Resveratrol and cancer: A review","volume":"56","author":"Savouret","year":"2002","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/bs.acr.2025.06.004_bib49","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1073\/pnas.0600445103","article-title":"Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides","volume":"103","author":"Schirmer","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.acr.2025.06.004_bib50","doi-asserted-by":"crossref","unstructured":"Schleicher, T. K., Cohen, M., & Graf, S. A. (2025). The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia.\u00a0Expert Opinion on Drug Discovery. https:\/\/doi.org\/10.1080\/17460441.2025.24653651-14.","DOI":"10.1080\/17460441.2025.2465365"},{"key":"10.1016\/bs.acr.2025.06.004_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10637-019-00776-6","article-title":"Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors","volume":"38","author":"Shapiro","year":"2020","journal-title":"Investigational New Drugs"},{"key":"10.1016\/bs.acr.2025.06.004_bib52","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1038\/s41598-024-81704-4","article-title":"Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer","volume":"15","author":"Shin","year":"2025","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.acr.2025.06.004_bib53","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1021\/jm9806603","article-title":"Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor","volume":"42","author":"Smaill","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2020.104492","article-title":"Furanocoumarins in anticancer therapy - for and against","volume":"142","author":"Sumorek-Wiadro","year":"2020","journal-title":"Fitoterapia"},{"key":"10.1016\/bs.acr.2025.06.004_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/0008-5472.CAN-15-3143","article-title":"Glutathione-associated enzymes in anticancer drug resistance","volume":"76","author":"Tew","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib56","first-page":"3622","article-title":"Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines","volume":"48","author":"Tew","year":"1988","journal-title":"Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib57","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1073\/pnas.1918164117","article-title":"The small molecule BI-2852 induces a nonfunctional dimer of KRAS","volume":"117","author":"Tran","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.acr.2025.06.004_bib58","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.2174\/1871520622666220408090541","article-title":"Recent advances in epidermal growth factor receptor inhibitors (EGFRIs) and their role in the treatment of cancer: A review","volume":"22","author":"Unnisa","year":"2022","journal-title":"Anti-cancer Agents in Medicinal Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib59","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1158\/1535-7163.MCT-07-0451","article-title":"The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent","volume":"6","author":"Vannini","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.acr.2025.06.004_bib60","article-title":"Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies","volume":"163","author":"Wang","year":"2023","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/bs.acr.2025.06.004_bib61","doi-asserted-by":"crossref","first-page":"7856","DOI":"10.1158\/0008-5472.CAN-07-0151","article-title":"Ethacrynic acid butyl-ester induces apoptosis in leukemia cells through a hydrogen peroxide mediated pathway independent of glutathione S-transferase P1-1 inhibition","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib62","doi-asserted-by":"crossref","first-page":"38954","DOI":"10.1074\/jbc.M203842200","article-title":"Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide","volume":"277","author":"Wen","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.acr.2025.06.004_bib63","doi-asserted-by":"crossref","unstructured":"Williamson, G., & Clifford, M. N. (2024). A critical examination of human data for the biological activity of quercetin and its phase-2 conjugates. Critical reviews in food science and nutrition. https:\/\/doi.org\/10.1080\/10408398.2023.22993291-37.","DOI":"10.1080\/10408398.2023.2299329"},{"key":"10.1016\/bs.acr.2025.06.004_bib64","first-page":"406","article-title":"FDA approves pralsetinib for treatment of adults with metastatic RET fusion-positive NSCLC","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/bs.acr.2025.06.004_bib65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/mol.106.030015","article-title":"The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from \u201cIndian winter cherry\u201d","volume":"71","author":"Yang","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.acr.2025.06.004_bib66","article-title":"Ethacrynic acid: A promising candidate for drug repurposing as an anticancer agent","volume":"24","author":"Yu","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.acr.2025.06.004_bib67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/bs.acr.2021.03.009","article-title":"Reductive stress in cancer","volume":"152","author":"Zhang","year":"2021","journal-title":"Advances in Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.004_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115929","article-title":"Adaptive changes in tumor cells in response to reductive stress","volume":"219","author":"Zhang","year":"2024","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.acr.2025.06.004_bib69","first-page":"876","article-title":"Combination of TLR7 agonist T7-ethacrynic acid conjugate with ROR1 has a stronger anti-breast cancer effect","volume":"32","author":"Zhang","year":"2016","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology"},{"key":"10.1016\/bs.acr.2025.06.004_bib70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.abb.2014.05.008","article-title":"The chalcones cardamonin and flavokawain B inhibit the differentiation of preadipocytes to adipocytes by activating ERK","volume":"554","author":"Zhang","year":"2014","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/bs.acr.2025.06.004_bib71","article-title":"Ethacrynic acid enhances the antitumor effects of afatinib in EGFR\/T790M-mutated NSCLC by inhibiting WNT\/beta-catenin pathway activation","volume":"2021","author":"Zhang","year":"2021","journal-title":"Disease Markers"},{"key":"10.1016\/bs.acr.2025.06.004_bib72","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1073\/pnas.89.6.2399","article-title":"A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure","volume":"89","author":"Zhang","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"}],"container-title":["Advances in Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X25000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X25000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:51:53Z","timestamp":1763549513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X25000193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443344817"],"references-count":72,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2025.06.004","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}